Safety and Efficacy of Elobixibat in Constipation - Echo 2

• Research type

  Research Study

• Full title

  A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period

• IRAS ID

  125774

• Contact name

  Essam Abdulhakim

• Contact email

  essam.hakim@synexus.com

• Sponsor organisation

  Ferring International Pharmascience Center US, Inc.

• Eudract number

  2012-005588-28

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  13/NW/0216

• Date of REC Opinion

  16 Apr 2013

• REC opinion

  Further Information Favourable Opinion